May 21, 2024
The National Advisory Committee on Immunization recommends BEYFORTUS® to protect all infants against RSV
Feb 23, 2021
Health Canada approves DUPIXENT® (dupilumab injection) as the first biologic for the treatment of moderate-to-severe atopic dermatitis in children aged 6 to 11 years
Aug 18, 2020
DUPIXENT® (dupilumab injection) now approved by Health Canada for severe chronic rhinosinusitis with nasal polyposis
Jul 08, 2020
SARCLISA(TM) (isatuximab for injection) now available in Canada for patients with relapsed and refractory multiple myeloma
Mar 02, 2020
Cablivi® (caplacizumab) approved by Health Canada for adults living with acquired thrombotic thrombocytopenic purpura (aTTP)
Mar 02, 2020
Cablivi® (caplacizumab) approved by Health Canada for adults living with acquired thrombotic thrombocytopenic purpura (aTTP)
Mar 02, 2020
Cablivi® (caplacizumab) approved by Health Canada for adults living with acquired thrombotic thrombocytopenic purpura (aTTP)
Jun 13, 2018
Canadian employers underestimate the proportion of their workforce with a chronic condition and its impact
May 16, 2018
Canadians living with diabetes can now access a new resource to help better manage their disease
Apr 12, 2018
Sanofi to invest EUR350 million in Canadian vaccine facility
Apr 10, 2018
Media Advisory - Sanofi to announce significant investment in Canadian vaccine production facility
Oct 17, 2017
Insulin in People Living with Type 2 Diabetes: Initiation and Dosage
May 29, 2017
The 20th Anniversary of The Sanofi Canada Healthcare Survey reveals surprising facts